The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic mushrooms as treatment for certain medical ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.